KA-3007 / KYinno - LARVOL DELTA

The bispecific antibody KA-3007 against B7H3 and CD28 enhances T cell activation in solid tumors (AACR 2024) - "Finally, we assessed the developability of KA-3007 with different treatments such as high concentration, low pH, repeated freezing and thawing, and high temperature, and it shows neither aggregation nor degradation. In conclusion, the BsAb KA-3007, developed with our common light chain antibody discovery platform, emerges as a promising pre-clinical candidate drug for the treatment of solid cancers."

IO biomarker • Oncology • Solid Tumor • CD276